Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Radiol Case Rep ; 15(5): 534-541, 2020 May.
Article in English | MEDLINE | ID: mdl-32180856

ABSTRACT

We report a case of a fibromyalgia (FM) patient with an history of brain-cancer presenting signs and symptoms of gadolinium toxicity following repeated administrations of a macrocyclic contrast agent, Gadovist. In the present report, we provide evidence supporting the hypothesis of a causal relationship linking gadolinium deposition to a clinical manifestation of disease, namely fibromyalgia. We unravel a role for gadolinium in the still unknown etiology of fibromyalgia as a metal toxicity disorder. Contrast agents are routinely administered in a clinical context. It is thus possible that the patients are mistakenly believed to show complaint of their primary disease, whereas, in some instances, their symptoms are associated with gadolinium deposition.

2.
J Neurol Sci ; 400: 175-179, 2019 May 15.
Article in English | MEDLINE | ID: mdl-30974322

ABSTRACT

Preoperative prognostic nutritional index (PNI) is linked to the clinical outcome of patients with malignant tumours, however few studies have investigated its utility in predicting outcome in glioblastoma multiforme (GBM). We performed a retrospective study on adult patients with GBM in order to evaluate the impact of PNI on overall survival (OS), after adjusting for known prognostic factor (age, extent of surgery, Karnofsky performance status, radiochemotherapy). This is an Italian, multicentre, retrospective, cohort study. The patient's cohort includes 282 individuals with a newly diagnosed GBM followed in 3 Lombardia Hospitals In all cases the diagnosis was supported by histological data. Patient's information including sex, age at onset, Karnofsky performance status (KPS), extension of surgical resection (EOR), adjuvant treatment, antiepileptic treatment, serum variables and survival data were collected. Univariate and multivariate analysis did not reveal an association between PNI and overall survival in our series of GBM patients. PNI is a controversial marker for prognosis in GBM patients and further prospective studies are necessary to elucidate its role.


Subject(s)
Brain Neoplasms/blood , Brain Neoplasms/epidemiology , Glioblastoma/blood , Glioblastoma/epidemiology , Nutrition Assessment , Adult , Aged , Aged, 80 and over , Anticonvulsants/therapeutic use , Brain Neoplasms/therapy , Cohort Studies , Female , Glioblastoma/therapy , Humans , Italy/epidemiology , Male , Middle Aged , Prognosis , Retrospective Studies
3.
Front Med (Lausanne) ; 5: 94, 2018.
Article in English | MEDLINE | ID: mdl-29761101

ABSTRACT

A 34-year-old woman suffered from significant chronic pain, depression, non-restorative sleep, chronic fatigue, severe morning stiffness, leg cramps, irritable bowel syndrome, hypersensitivity to cold, concentration difficulties, and forgetfulness. Blood tests were negative for rheumatic disorders. The patient was diagnosed with Fibromyalgia syndrome (FMS). Due to the lack of effectiveness of pharmacological therapies in FMS, she approached a novel metabolic proposal for the symptomatic remission. Its core idea is supporting serotonin synthesis by allowing a proper absorption of tryptophan assumed with food, while avoiding, or at least minimizing the presence of interfering non-absorbed molecules, such as fructose and sorbitol. Such a strategy resulted in a rapid improvement of symptoms after only few days on diet, up to the remission of most symptoms in 2 months. Depression, widespread chronic pain, chronic fatigue, non-restorative sleep, morning stiffness, and the majority of the comorbidities remitted. Energy and vitality were recovered by the patient as prior to the onset of the disease, reverting the occupational and social disabilities. The patient episodically challenged herself breaking the dietary protocol leading to its negative test and to the evaluation of its benefit. These breaks correlated with the recurrence of the symptoms, supporting the correctness of the biochemical hypothesis underlying the diet design toward remission of symptoms, but not as a final cure. We propose this as a low risk and accessible therapeutic protocol for the symptomatic remission in FMS with virtually no costs other than those related to vitamin and mineral salt supplements in case of deficiencies. A pilot study is required to further ground this metabolic approach, and to finally evaluate its inclusion in the guidelines for clinical management of FMS.

4.
J Neurol Sci ; 390: 14-19, 2018 07 15.
Article in English | MEDLINE | ID: mdl-29801876

ABSTRACT

Glioblastoma multiforme (GBM) has a dismal prognosis even with the best available treatment. Different studies have suggested a possible impact of antiepileptic drugs (AED) on survival in patients with GBM. A recent pooled analysis of prospective clinical trials in newly diagnosed GBM found no significant survival benefit in GBM patients treated with AED. We performed a retrospective study on adult patients with GBM in order to evaluate the impact of AED therapy on overall survival (OS), after adjusting for known prognostic factor (age, extent of surgery, Karnofsky performance status, radiochemotherapy). A total of 285 patients were analyzed. Of them 144 received a non-enzyme-inducing (NEIAED) and 95 an enzyme-inducing AED (EIAED). At univariate analysis the OS of patients receiving AED was not significantly different from that of patients not receiving an AED (HR 0.98, 95%CI 0.69-1.4, p = 0.925), moreover OS was not significantly different between patients receiving EIAED or NEIAED. At multivariate analysis a trend to more prolonged survival (HR 0.8, 95% CI 0.59-1.08, p = 0.15) was detected in patients treated with NEIAED. The question whether treatment with AED may increase OS in GBM patients remains unanswered and randomized extremely large controlled clinical trial would be necessary to elucidate the possible impact of AED on prognosis. In the meantime the use of AED in GBM patients, based on the presumed potential antitumour activity, is not recommended.


Subject(s)
Anticonvulsants/therapeutic use , Brain Neoplasms/mortality , Brain Neoplasms/therapy , Glioblastoma/mortality , Glioblastoma/therapy , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Italy/epidemiology , Kaplan-Meier Estimate , Male , Middle Aged , Seizures/drug therapy , Seizures/epidemiology , Treatment Outcome
5.
J Neurol Sci ; 378: 3-8, 2017 Jul 15.
Article in English | MEDLINE | ID: mdl-28566172

ABSTRACT

The appropriate treatment approach for elderly patients with glioblastoma multiforme (GBM) is unclear, although different studies suggest survival benefit in fit patients treated with radiotherapy and chemiotherapy after surgery. We performed a retrospective analysis of 151 patients older than 65years with GBM treated in 3 Lombardia Hospitals. In univariate regression analysis higher KPS (p=0.02), macroscopical total resection (p<0.003), radiotherapy (p<0.0001), chemotherapy (p<0.0001) and second line chemotheraphy (p=0.02) were of positive prognostic value. On the contrary older age (>70years), presence of seizure at onset and additional resection after tumor recurrence did not influence OS. Multivariate analysis revealed radiotherapy (HR 0.2 p<0.0001) and extent of surgery (HR 0.3, p=0,0063) as positive independent prognostic factors. Patients receiving radio-chemiotherapy displayed more treatment-related toxicities with a slightly prolonged OS versus those receiving hypofractionated radiotherapy. With the limits of a retrospective study, our data suggest that in elderly fit patients extensive surgery should be considered, moreover adjuvant treatments led to an increase in OS. Randomized controlled study are needed to develop treatment guidelines for elderly GBM patients and to assess whether the combination of post-surgical radio and chemiotherapy may be superior to hypofractionated radiotherapy and chemiotherapy in fit patients.


Subject(s)
Brain Neoplasms/therapy , Glioblastoma/therapy , Aged , Aged, 80 and over , Combined Modality Therapy , Female , Humans , Kaplan-Meier Estimate , Male , Multivariate Analysis , Neurosurgical Procedures , Proportional Hazards Models , Regression Analysis , Retrospective Studies , Treatment Outcome
6.
BMJ Case Rep ; 20132013 Aug 02.
Article in English | MEDLINE | ID: mdl-23912659

ABSTRACT

A previously healthy man underwent endoscopic biopsy for a suspected pineal germinoma. Histology and immunohistochemistry did not confirm the preoperative diagnosis, and neurosarcoidosis was hypothesised because of the presence of granulomatous reaction. The patient remained in good health for 3 years and was still asymptomatic when a control MRI showed metastasis implantation along the endoscopic route. A redobiopsy provided the diagnosis of germinoma, but was complicated by severe ventricular haemorrhage requiring emergency clot excision. Postoperative clinical conditions were so severe that the treatment of germinoma was postponed. Three months later, repeated MRI showed tumour progression. Chemotherapy promoted good tumour regression so that the treatment was completed by radiation therapy. The tumour completely disappeared on MRI, but the patient remained severely disabled because of the haemorrhage.


Subject(s)
Brain Neoplasms/diagnosis , Central Nervous System Diseases/diagnosis , Germinoma/diagnosis , Pineal Gland , Sarcoidosis/diagnosis , Adult , Diagnosis, Differential , Endoscopy/adverse effects , Germinoma/secondary , Humans , Male , Neoplasm Seeding
7.
Neurol Sci ; 29(2): 77-83, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18483704

ABSTRACT

A prospective collection of newly diagnosed cases of grade IV glioma in Lombardia, Italy, was started in 2003. In the present report, data are shown on 349 adult patients recruited up to 2005. The clinical features, pattern of care and outcome are discussed, together with the main prognostic factors. Males were affected more frequently than women; median age at onset was 60. Overall, gross total tumour resection was performed in roughly 50% of the patients, and partial resection and biopsy in 25% each; only 5 patients did not undergo histology. Adjuvant radiotherapy was delivered to 89% and chemotherapy to 82% of patients. Median survival was of 54 weeks. Most patients received protracted therapy with antiepileptic drugs, despite absence of seizures; over the course of the study, the practice pattern tended to change, shifting to the use of non-enzyme-inducing anti-epileptic drugs.


Subject(s)
Brain Neoplasms/diagnosis , Brain Neoplasms/therapy , Glioblastoma/diagnosis , Glioblastoma/therapy , Adolescent , Adult , Age Distribution , Age of Onset , Aged , Aged, 80 and over , Anticonvulsants/therapeutic use , Biopsy , Brain Neoplasms/epidemiology , Clinical Protocols , Databases, Factual , Drug Therapy/methods , Drug Therapy/statistics & numerical data , Drug Therapy/trends , Epilepsy/drug therapy , Epilepsy/etiology , Epilepsy/prevention & control , Female , Glioblastoma/epidemiology , Humans , Italy/epidemiology , Male , Middle Aged , Neurosurgical Procedures/methods , Neurosurgical Procedures/statistics & numerical data , Neurosurgical Procedures/trends , Prognosis , Prospective Studies , Radiotherapy/methods , Radiotherapy/statistics & numerical data , Radiotherapy/trends , Sex Distribution , Survival Rate , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL